• PD Neurotechnology targets €500K on SeedBlink as a part of €5M Series A round led by CIC Capital Partners and BigPi Ventures, both of them participating with a total of €4.5M
• The Greek medtech startup provides patients with medical wearables and advanced AI software for monitoring and treatment
• Funds will be used for manufacturing purposes, clinical trials and to boost business development in new markets
After having raised €4.5M, Greek medtech startup PD Neurotechnology announced that it is targeting €500K in a financing round opened by SeedBlink, the European co-investment platform in tech startups, as a part of Series A round worth €5M.
Neurotechnology provides patients with Parkinson’s Disease and other movement disorders with medical wearables and advanced AI software for monitoring and treatment, which can be applied at home or in non-clinical settings.
Founded in 2015, the Greek startup’s team includes 40 specialists in biomedical devices, neurology, healthcare, logistics, artificial intelligence and Parkinson’s Disease, with an advisory board that includes neurology and Parkinson’s Disease scientists.
Investing in clinical trials and developing in new markets
According to PD Neurotechnology, the funds raised in this investment round will be used for manufacturing purposes, clinical trials, and to boost business development in new markets.
“Our goal has always been to develop innovative and non-invasive solutions to help patients feel safer, and forge a close and effective doctor-patient relationship. Our plans for the future are substantial, we are constantly looking for new sources of growth and we always seek to diversify and enhance the solutions we provide,” Nikos Moschos, founder and Business Director of Neurotechnology said in a statement.
For SeedBlink, supporting medtech innovators is of great importance since it provides them with the ability to come up with effective solutions.
“It is important that we back MedTech innovators, as they not only impact the economy, but they improve people’s lives. We need to strengthen their ability to provide efficient solutions. Meaningful innovation makes our investment all the more meaningful. We are enthusiastic about PD Neurotechnology’s products and are keen to support their growth,” Ionuț Pătrăhău, managing director and corporate development at SeedBlink, concluded.
Currently, PD Neurotechnology’s sales and marketing is based in Athens, while its R&D and production is in the city of Ioannina. The Greek company operates in 13 European countries, and its US launch is planned for the last quarter ofof 2022.
